SCOPOLAMINE

First marketed in 1899

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H21NO4
Molecular Weight	303.3529
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12O[C@]1([H])[C@H]3C[C@H](C[C@@H]2N3C)OC(=O)[C@H](CO)C4=CC=CC=C4

InChI

InChIKey=STECJAGHUSJQJN-FWXGHANASA-N

InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C17H21NO4
Molecular Weight	303.3529
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16175141 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf

The alkaloid L-(-)-scopolamine [L-(-)-hyoscine], a belladonna alkaloid, competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous system, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center. Scopolamine can inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase heart rate, and depress motor function. Scopolamine is used for premedication in anesthesia and for the prevention of nausea and vomiting (post operative and associated with motion sickness).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 3 (5-HT3) receptor 58 Target ID: CHEMBL2094132 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27108935	Antagonist 2737		2.09 µM [IC50]
Muscarinic acetylcholine receptor 159 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1727135 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Antagonist 2737

Conditions

Condition	Modality	Highest Phase	Product
Motion sickness 43 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Preventing	Approved 8307	TRANSDERM SCOP Approved Use Transderm Scōp is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with: Motion Sickness and Post Operative Nausea and Vomiting (PONV) Launch Date 3.15446395E11
Postoperative nausea and vomiting 29 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Preventing	Approved 8307	TRANSDERM SCOP Approved Use Transderm Scōp is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with: Motion Sickness and Post Operative Nausea and Vomiting (PONV) Launch Date 3.15446395E11
Depression 232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17015814 https://www.ncbi.nlm.nih.gov/pubmed/23334071	Primary	Phase IV 63	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
5 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
369 ng × min/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
9.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
68.7 min REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
70% REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years n = 12 Health Status: healthy Age Group: 21 - 47 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	Other AEs: Dizziness, Lightheadedness... Other AEs: Dizziness (3 patients) Lightheadedness (3 patients) Nasal burning (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years n = 35 Health Status: healthy Age Group: 21.4 years Sex: M Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	Other AEs: Blurred vision, Dizziness... Other AEs: Blurred vision Dizziness Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
6 ug/kg single, intravenous Dose: 6 ug/kg Route: intravenous Route: single Dose: 6 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 22.8 years n = 9 Health Status: healthy Age Group: 22.8 years Sex: M Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) n = 12 Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	Other AEs: Dizziness, Dry mouth... Other AEs: Dizziness (4 patients) Dry mouth (3 patients) Blurred vision (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years n = 1 Health Status: unhealthy Age Group: 83 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	Other AEs: Consciousness abnormal, Hyperthermia... Other AEs: Consciousness abnormal (1 patient) Hyperthermia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25395072
0.5 mg single, intravenous Dose: 0.5 mg Route: intravenous Route: single Dose: 0.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15792397	healthy, adult n = 6 Health Status: healthy Age Group: adult Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15792397	Sources: https://pubmed.ncbi.nlm.nih.gov/15792397

AEs

AE	Significance	Dose	Population
Nasal burning	1 patient	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years n = 12 Health Status: healthy Age Group: 21 - 47 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Dizziness	3 patients	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years n = 12 Health Status: healthy Age Group: 21 - 47 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Lightheadedness	3 patients	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years n = 12 Health Status: healthy Age Group: 21 - 47 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Blurred vision		0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years n = 35 Health Status: healthy Age Group: 21.4 years Sex: M Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
Dizziness		0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years n = 35 Health Status: healthy Age Group: 21.4 years Sex: M Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
Dry mouth	3 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) n = 12 Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Blurred vision	4 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) n = 12 Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Dizziness	4 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) n = 12 Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Consciousness abnormal	1 patient	10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years n = 1 Health Status: unhealthy Age Group: 83 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25395072
Hyperthermia	1 patient	10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years n = 1 Health Status: unhealthy Age Group: 83 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25395072

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 753 inhibitor 1532	inhibitor 1695	inhibitor 1789

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2C8 869 CYP2C19 1410 OCT1 498 OCT2 630 OCT3 143 MATE1 302 MATE2 259	CYP3A 188	CYP1A2 671

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1620	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C8 923	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP3A4 1857	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP3A4 1857	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
MATE1 304	inhibitor 3185 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 119.2 uM]
OCT3 143	inhibitor 3185 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 217.9 uM]
OCT2 631	inhibitor 3185 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 540.8 uM]
OCT1 513	inhibitor 3185 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 6.7 uM]
MATE2 259	inhibitor 3185 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 699.9 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A 188	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/16175141/	yes		yes (co-administration study) Comment: The AUC0–24h values of scopolamine were higher during the grapefruit juice period. They reached approximately 142% of the values associated with the control group (water period; P . 0.005) Sources: https://pubmed.ncbi.nlm.nih.gov/16175141/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:16794	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16794
MolPort	MolPort-005-938-576	https://www.molport.com/shop/molecule-link/MolPort-005-938-576
ZINC	ZINC000100037020	http://zinc15.docking.org/substances/ZINC000100037020

PubMed

Title	Date	PubMed
Scopolamine does not restore normal conditioned avoidance performance in raclopride-treated rats.	2001	11475009
Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test.	2001	11440810
Interactions between cholinergic and GABAergic neurotransmitters in and around the locus coeruleus for the induction and maintenance of rapid eye movement sleep in rats.	2001	11377848
Dopaminergic lateralisation in the forebrain: relations to behavioural asymmetries and anxiety in male Wistar rats.	2001	11287799
Glucose plus choline improve passive avoidance behaviour and increase hippocampal acetylcholine release in mice.	2001	11246151
Muscarinic cholinergic and glutamatergic reciprocal regulation of expression of hippocampal cholinergic neurostimulating peptide precursor protein gene in rat hippocampus.	2001	11166120
Effects of MDL 73005 on water-maze performances and locomotor activity in scopolamine-treated rats.	2001 Apr	11526961
Male-female differences in rat hypothalamic-pituitary-adrenal axis responses to nicotine stimulation.	2001 Apr	11403996
Decreased scopolamine yield in field-grown Duboisia plants regenerated from hairy roots.	2001 Apr	11345697
Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase.	2001 Apr	11299326
Tiotropium bromide.	2001 Apr	11281822
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.	2001 Apr 27	11392629
Antimuscarinic treatment for lung diseases from research to clinical practice.	2001 Apr 27	11392626
M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation.	2001 Apr 27	11392612
Ultrasonic vocalizations as an index of social memory in female mice.	2001 Aug	11508722
Cholinergic synaptic potentials in the supragranular layers of auditory cortex.	2001 Aug	11400178
Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm.	2001 Feb	11346312
Differences in parasympathetic vasodilator and salivary responses in the cat submandibular gland between lingual and chorda-lingual nerve stimulation.	2001 Feb	11332537
Neural mechanisms of motion sickness.	2001 Feb	11286016
Reversal caused by n-butylidenephthalide from the deficits of inhibitory avoidance performance in rats.	2001 Feb	11270720
Inhaled anticholinergic therapy: applied pharmacology and interesting developments.	2001 Jan	11527013
Enterostatin (VPDPR) has anti-analgesic and anti-amnesic activities.	2001 Jan	11272841
Tropane alkaloid production by shoot culture of Duboisia myoporoides R. Br.	2001 Jan	11198820
Designing of an orally active complement C3a agonist peptide with anti-analgesic and anti-amnesic activity.	2001 Jan	11179594
Influence of cholinergic system on motor learning during aging in mice.	2001 Jan 29	11164519
Developmental exposure to methylmercury alters behavioral sensitivity to D-amphetamine and pentobarbital in adult rats.	2001 Jan-Feb	11274875
Occurrence of cadaverine in hairy roots of Brugmansia candida.	2001 Jul	11397445
Anti-ischemic and cognition-enhancing properties of NNC-711, a gamma-aminobutyric acid reuptake inhibitor.	2001 Jul 13	11470258
Effects of vasopressin on histamine H(1) receptor antagonist-induced spatial memory deficits in rats.	2001 Jul 6	11448481
Interaction between the cholinergic system and CRH in the modulation of spatial discrimination learning in mice.	2001 Jul 6	11430861
Drug-induced variations in the probability of occurrence of multiple corrective saccades.	2001 Jun	11453194
The alpha 2 adrenoceptor antagonists RX 821002 and yohimbine delay-dependently impair choice accuracy in a delayed non-matching-to-position task in rats.	2001 Jun	11441427
Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum.	2001 Jun	11399661
Dose- and time-dependent scopolamine-induced recovery of an inhibitory avoidance response after its extinction in rats.	2001 Jun	11275294
Role of 5-HT(1A) and 5-HT(7) receptors in the facilitatory response induced by 8-OH-DPAT on learning consolidation.	2001 Jun	11275281
Coadministration of intrathecal strychnine and bicuculline effects synergistic allodynia in the rat: an isobolographic analysis.	2001 Mar	11181903
Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies.	2001 Mar	11181892
Comparative effects of scopolamine and quinpirole on the striatal fos expression induced by stimulation of D(1) dopamine receptors in the rat.	2001 Mar 2	11223008
Memory impairment induced by cholinergic antagonists injected into the mushroom bodies of the honeybee.	2001 May	11467497
Subchronic administration of various pretreatments of nerve agent poisoning. II. Compared efficacy against soman toxicity.	2001 May	11360433
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.	2001 May	11303071
Intrahippocampal scopolamine impairs both acquisition and consolidation of contextual fear conditioning.	2001 May	11300731
Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo.	2001 May	11297908
Excitatory nicotinic and desensitizing muscarinic (M2) effects on C-nociceptors in isolated rat skin.	2001 May 1	11312314
The role of muscarinic cholinoceptors in the retrieval of an operant food-related conditioned reflex in cats.	2001 May-Jun	11430573
The acetylcholine release enhancer linopirdine induces Fos in neocortex of aged rats.	2001 May-Jun	11378256
Antihyperalgesic effects of the muscarinic receptor ligand vedaclidine in models involving central sensitization in rats.	2001 Sep	11514081
Substance P and its transglutaminase-synthesized spermine derivative elicit yawning behavior via nitric oxide in rats.	2001 Sep	11514028
Pharmacological modulation of behavioral and neuronal correlates of repetition priming.	2001 Sep 1	11517272
Simultaneous modulation of retrieval by dopaminergic D(1), beta-noradrenergic, serotonergic-1A and cholinergic muscarinic receptors in cortical structures of the rat.	2001 Sep 28	11423160

Patents

Sample Use Guides

In Vivo Use Guide

Transderm Scōp (scopolamine) transdermal system patch. Each Transderm Scōp patch is formulated to deliver in-vivo approximately 1 mg of scopolamine over 3 days. Initiation of Therapy Motion Sickness To prevent the nausea and vomiting associated with motion sickness, one Transderm Scōp patch (formulated to deliver approximately 1 mg of scopolamine over 3 days) should be applied to the hairless area behind one ear at least 4 hours before the antiemetic effect is required. Post Operative Nausea and Vomiting To prevent post operative nausea and vomiting, one Transderm Scōp patch should be applied the evening before scheduled surgery, except for caesarian section. For caesarian section surgery, to minimize exposure of the newborn baby to the drug, apply the patch one hour prior to caesarian section. Continuation of Therapy Should the patch become displaced, it should be discarded, and a fresh one placed on the hairless area behind the other ear. Motion Sickness If therapy is required for longer than 3 days, the first patch should be removed and a fresh one placed on the hairless area behind the other ear. Post Operative Nausea and Vomiting For perioperative use, the patch should be kept in place for 24 hours following surgery at which time it should be removed and discarded.

Route of Administration: Transdermal

In Vitro Use Guide

Rosmarinic acid treatment increases the expression of BDNF and GluR-2 proteins and prevents cell death of scopolamine-exposed (300 μM) organotypic hippocampal slice cultures.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 20:27:16 UTC 2022` Edited by `admin` on `Fri Dec 16 20:27:16 UTC 2022`
Record UNII	DL48G20X8X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SCOPOLAMINE

Common Name

English

HYOSCINE [EP MONOGRAPH]

Common Name

English

SCOPOLAMINE [MI]

Common Name

English

SCOPOLAMINE [USP IMPURITY]

Common Name

English

SCOPOLAMINE [ORANGE BOOK]

Common Name

English

HYOSCINE [EP IMPURITY]

Common Name

English

HYOSCINE

Common Name

English

SCOPOLAMINE [VANDF]

Common Name

English

BENZENEACETIC ACID, .ALPHA.(HYDROXYMETHYL)-,(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (.ALPHA.S)-

Common Name

English

6.BETA.,7.BETA.-EPOXY-1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (-)-TROPATE (ESTER)

Common Name

English

BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, 9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-

Common Name

English

(1R,2R,4S,5S,7S)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL (2S)-3-HYDROXY-2-PHENYLPROPANOATE

Common Name

English

HYOSCINE [MART.]

Common Name

English

ATROPINE SULFATE IMPURITY F [EP IMPURITY]

Common Name

English

SCOPOLAMINE [HSDB]

Common Name

English

Hyoscine [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A04AD51